• Anagliptin-Induced Vasorelaxation: Kv Channel and SERCA Pump

  2026-07-27

  This study provides the first direct evidence that anagliptin, a DPP-4 inhibitor, induces vasorelaxation in rabbit aortic smooth muscle via activation of voltage-dependent K+ (Kv) channels and the SERCA pump. The findings delineate endothelium-independent pathways, highlighting new mechanisms relevant to cardiovascular risk modulation in diabetes research.

• YC-1: Advancing Hypoxia Pathway Research in Translational On

  2026-07-27

  This article delivers a strategic exploration of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, focusing on its mechanistic role as a soluble guanylyl cyclase activator and HIF-1α inhibitor. It guides translational researchers through biological rationale, experimental protocols, and the product's competitive edge, referencing state-of-the-art assay standards and broader translational implications.

• Sitagliptin Phosphate Monohydrate: DPP-4 Inhibition in Resea

  2026-07-26

  Sitagliptin phosphate monohydrate is a selective DPP-4 inhibitor central to type II diabetes treatment research and incretin hormone modulation. Its high potency, well-defined mechanism, and robust experimental benchmarks make it a preferred tool for metabolic disease models. This dossier details its molecular action, validated applications, and practical workflow guidance.

• WST-8 Glucose Uptake Assay Kit: Advanced Workflows & Trouble

  2026-07-25

  The WST-8 Glucose Uptake Assay Kit streamlines non-radioactive, quantitative measurement of cellular glucose uptake with robust sensitivity and rapid readout. This guide explores optimized protocols, advanced experimental strategies, and practical troubleshooting tailored for metabolic research, cancer metabolism, and diabetes studies.

• CFTRinh-172 in Translational CFTR Modulation: Mechanistic In

  2026-07-24

  Explore how CFTRinh-172, a highly selective CFTR inhibitor, advances cystic fibrosis and secretory diarrhea research through mechanistic precision and evidence-based protocol guidance. This article uniquely connects CFTR trafficking, inhibitor specificity, and translational assay optimization.

• Exendin-4: Mechanistic Insights and Innovations for Beta Cel

  2026-07-24

  Explore the cutting-edge science behind Exendin-4, a GLP-1 receptor agonist pivotal for insulin sensitivity improvement and advanced beta cell research. This article delivers unique mechanistic depth and practical protocol guidance not found elsewhere.

• Exendin-4: Practical Workflows and Innovations for Beta Cell

  2026-07-23

  Exendin-4 is a gold-standard GLP-1 receptor agonist for probing beta cell function and insulin sensitivity in type 2 diabetes research. This article distills advanced workflows, experimental pitfalls, and recent breakthroughs—like stable yeast expression—into actionable guidance for translational scientists.

• GDC-0068 (RG7440) Pan-AKT Inhibitor: Reliable PI3K/Akt/mTOR

  2026-07-23

  This article addresses real-world challenges in cell viability and PI3K/Akt/mTOR pathway research, demonstrating how GDC-0068 (RG7440) Pan-AKT Inhibitor (SKU A3006) from APExBIO offers data-backed solutions for reproducible, selective Akt inhibition. Scenario-driven Q&As guide laboratory scientists through protocol optimization, data interpretation, and informed product selection.

• Exendin-4: Applied Workflows for Insulin Sensitivity Researc

  2026-07-22

  Exendin-4 (Exenatide) empowers type 2 diabetes research by enabling precise modeling of insulin sensitivity improvement and hepatic steatosis reversal. This guide translates bench-proven protocols and recent workflow innovations into actionable steps, troubleshooting advice, and strategic perspectives for advanced beta cell function studies.

• JNK-IN-7: Selective JNK Inhibitor for Apoptosis Pathway Rese

  2026-07-22

  JNK-IN-7 empowers researchers to dissect MAPK and Toll receptor signaling with extraordinary specificity, enabling nuanced analysis of apoptosis and immune pathways. Its covalent selectivity and robust performance position it as an indispensable tool for cell-based kinase assays and mechanistic studies in inflammation and apoptosis.

• A-1331852: Precision BCL-XL Inhibition for Advanced Apoptosi

  2026-07-21

  A-1331852, a highly selective BCL-XL inhibitor from APExBIO, delivers unparalleled potency and specificity for apoptosis assays and targeted cancer research. This guide translates mechanistic advances and workflow optimizations into actionable strategies for robust, reproducible results—addressing both practical setup and troubleshooting for next-generation studies.

• EdU Imaging Kits (Cy5): Advanced S-Phase DNA Synthesis Detec

  2026-07-21

  EdU Imaging Kits (Cy5) unlock high-sensitivity, morphology-preserving measurement of cell proliferation, outperforming legacy BrdU assays for both microscopy and flow cytometry. Explore optimized workflows, troubleshooting tactics, and translational applications in genotoxicity and stem cell research.

• WST-8 Glucose Uptake Assay Kit: Precision in Metabolic Analy

  2026-07-20

  The WST-8 Glucose Uptake Assay Kit streamlines non-radioactive, quantitative measurement of cellular glucose uptake, empowering research in metabolism, diabetes, and cancer. With robust sensitivity, a colorimetric readout, and compatibility with complex metabolic models, this APExBIO solution delivers actionable insights into metabolic dysfunction and therapeutic intervention.

• A20 Modulates Oxidized Self-DNA-Driven Inflammation in AKI

  2026-07-20

  The reference study elucidates how the ubiquitin-editing enzyme A20 attenuates inflammation driven by oxidized self-DNA in acute kidney injury (AKI), primarily by disrupting NLRP3 inflammasome activation via NEK7 interference. These mechanistic insights refine our understanding of inflammation pathways in AKI and offer new avenues for translational intervention targeting sterile inflammatory processes.

• Everolimus (RAD001): Deep Mechanistic Insights for mTOR Path

  2026-07-19

  Explore the advanced mechanistic underpinnings and research protocols of Everolimus (RAD001), a potent mTOR pathway inhibitor. This article offers a unique, evidence-based perspective on optimizing experimental design and interpreting drug responses in cancer research.

16111 records 1/1075 page Next 12345 下5页 Last page